Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.57 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760865 | 1.00 | ANPEP (0.57) | ANPEPERAP1ERAP2METAP2METAP1 | |
| SCHEMBL194645 | 1.00 | ANPEP (0.57) | ANPEPERAP1ERAP2METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL28675057 | 0.98 | ANPEP (0.55) | ANPEPERAP1ERAP2METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL20590185 | 0.98 | ANPEP (0.55) | ANPEPERAP1ERAP2METAP2METAP1 | |
| Hydrochloric Acid SCHEMBL16988 | 0.98 | ANPEP (0.55) | ANPEPERAP1ERAP2METAP2METAP1 | |
| Sulfuric Acid SCHEMBL1605647 | 0.90 | BLM (0.55) | ANPEPERAP1ERAP2METAP2METAP1 | |
| Nitric Acid SCHEMBL7055225 | 0.87 | ANPEP (0.50) | ANPEPERAP1ERAP2METAP2METAP1 | |
| SCHEMBL7998233 | 0.86 | GRIK1 (0.54) | ANPEPERAP1ERAP2HTR2ASMN1; SMN2 | |
| SCHEMBL456442 | 0.86 | GRIK1 (0.54) | ANPEPERAP1ERAP2HTR2ASMN1; SMN2 | |
| SCHEMBL14544283 | 0.86 | GRIK1 (0.54) | ANPEPERAP1ERAP2HTR2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880721-B | Synthesis method of dapoxetine | 湖南九典制药股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-113880721-A | Synthetic method of dapoxetine | 湖南九典制药股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| EP-1250119-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2007-10-03 | — | — | EP | claimed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | claimed |
| CN-113880721-B | Synthesis method of dapoxetine | 湖南九典制药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-113880721-B | Synthesis method of dapoxetine | 湖南九典制药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-113880721-A | Synthetic method of dapoxetine | 湖南九典制药股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113880721-A | Synthetic method of dapoxetine | 湖南九典制药股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-8937100-B2 | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20140086863-A1 | Cosmetic Composition | COGNIS IP MANAGEMENT GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592484-B2 | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing | COGNIS IP MANAGEMENT GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| CN-101531668-A | (3s)-3-benzyl-7a-(trifluoromethyl) tetrahydropyrrolo [2, 1-b] oxazole-5(6H)-ketone and synthetic method thereof | UNIV SHANGHAI | 2009-09-16 | — | — | CN | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2008132128-A2 | SYNTHESIS OF A PHARMACEUTICALLY ACTIVE COMPOUND | Solvay (Société Anonyme) (BE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1250119-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2007-10-03 | — | — | EP | disclosed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | ANPEP 3524/4885ERAP1 1009/4885ERAP2 833/4885 |
| US-20140086863-A1 | Cosmetic Composition | ASAH2, ASAH1, GLA | ANPEP 365/4885ERAP1 189/4885ERAP2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.